Free Trial
→ M.A.G.A. is Finished – This Could be even Better (From Paradigm Press) (Ad) Buy LENZ Stock  Free LENZ Stock Alerts

LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$27.04 +0.09 (+0.33%)
As of 10:29 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -101 -70 -50
Consolidated Net Income / (Loss)		 -101 -70 -50
Net Income / (Loss) Continuing Operations		 -101 -70 -50
Total Pre-Tax Income 		-101 -70 -50
Total Operating Income		 -106 -72 -59
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 106 72 59
Selling, General & Admin Expense		 33 13 29
Research & Development Expense		 73 60 30
Total Other Income / (Expense), net		 4.59 2.28 8.84
Interest & Investment Income		 - 2.19 8.55
Other Income / (Expense), net		 4.59 0.09 0.29
Income Tax Expense		 - -0.18 0.00
Basic Earnings per Share		 ($1.84) ($35.71) ($2.34)
Weighted Average Basic Shares Outstanding		 54.87M 1.96M 21.28M
Diluted Earnings per Share		 ($1.84) ($35.71) ($2.34)
Weighted Average Diluted Shares Outstanding		 54.87M 1.96M 21.28M
Weighted Average Basic & Diluted Shares Outstanding		 58.16M 58.24M 27.54M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13
Consolidated Net Income / (Loss)		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13
Net Income / (Loss) Continuing Operations		 -25 -24 -13 -15 -19 -24 -17 -10 -10 -13
Total Pre-Tax Income 		-25 -24 -13 -15 -19 -24 -17 -10 -10 -13
Total Operating Income		 -26 -27 -13 -15 -20 -25 -16 -14 -13 -15
Total Operating Expenses		 26 27 13 15 20 25 16 14 13 15
Selling, General & Admin Expense		 7.85 8.29 2.29 2.32 2.86 5.45 5.55 7.41 6.49 9.36
Research & Development Expense		 18 18 10 13 17 20 11 6.95 6.45 5.87
Total Other Income / (Expense), net		 1.47 2.28 -0.05 0.23 0.99 1.12 -0.56 4.10 2.73 2.57
Interest & Investment Income		 - - 0.00 0.25 1.09 0.85 0.79 2.46 2.74 2.57
Other Income / (Expense), net		 1.47 2.28 -0.05 -0.02 -0.10 0.27 -1.35 1.64 -0.01 0.01
Basic Earnings per Share		 ($0.45) ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97
Weighted Average Basic Shares Outstanding		 55.21M 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M
Diluted Earnings per Share		 ($0.45) ($0.43) ($6.50) ($7.53) ($9.62) ($12.06) ($3.53) ($0.40) ($0.38) $1.97
Weighted Average Diluted Shares Outstanding		 55.21M 54.87M 1.95M 1.96M 1.96M 1.96M 4.72M 25.61M 27.17M 21.28M
Weighted Average Basic & Diluted Shares Outstanding		 58.15M 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents		 -329 -9.30 -15
Net Cash From Operating Activities		 -88 -60 -59
Net Cash From Continuing Operating Activities		 -88 -60 -59
Net Income / (Loss) Continuing Operations		 -101 -70 -50
Consolidated Net Income / (Loss)		 -101 -70 -50
Depreciation Expense		 2.35 0.02 0.06
Amortization Expense		 -1.60 -1.06 -4.02
Non-Cash Adjustments To Reconcile Net Income		 20 1.41 7.43
Changes in Operating Assets and Liabilities, net		 -7.30 9.41 -13
Net Cash From Investing Activities		 -242 -30 -154
Net Cash From Continuing Investing Activities		 -242 -30 -154
Purchase of Property, Plant & Equipment		 -6.59 -0.03 -0.47
Purchase of Investments		 -406 -52 -242
Sale and/or Maturity of Investments		 170 23 88
Net Cash From Financing Activities		 0.60 81 199
Net Cash From Continuing Financing Activities		 0.60 81 199
Repurchase of Common Equity		 -0.08 -2.48 0.00
Issuance of Preferred Equity		 - 83 0.00
Issuance of Common Equity		 0.66 0.00 80
Other Financing Activities, net		 0.02 0.20 119

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -19 -8.66 70 -40 -32 -7.71 165 -116 -43 -21
Net Cash From Operating Activities		 -22 -22 -13 -14 -13 -21 -24 -16 -11 -9.08
Net Cash From Continuing Operating Activities		 -22 -22 -13 -14 -13 -21 -24 -16 -11 -9.08
Net Income / (Loss) Continuing Operations		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13
Consolidated Net Income / (Loss)		 -25 -25 -13 -15 -19 -24 -17 -10 -10 -13
Depreciation Expense		 0.65 0.68 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.03
Amortization Expense		 -0.56 -1.12 0.00 -0.02 -0.53 -0.51 -0.28 -0.96 -1.36 -1.42
Non-Cash Adjustments To Reconcile Net Income		 4.62 5.53 0.16 0.21 0.60 0.44 1.99 1.60 2.19 1.65
Changes in Operating Assets and Liabilities, net		 -2.24 -2.92 -0.29 1.00 5.72 2.98 -9.01 -6.20 -1.21 3.33
Net Cash From Investing Activities		 3.50 14 -0.01 -27 -18 15 18 -98 -62 -12
Net Cash From Continuing Investing Activities		 3.50 14 -0.01 -27 -18 15 18 -98 -62 -12
Purchase of Property, Plant & Equipment		 -0.92 -1.02 -0.01 -0.02 - - 0.00 -0.13 -0.19 -0.15
Purchase of Investments		 -86 -66 - - -19 -5.83 - - -84 -47
Sale and/or Maturity of Investments		 90 80 0.00 - 1.50 21 18 13 22 35
Net Cash From Financing Activities		 -0.06 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05
Net Cash From Continuing Financing Activities		 -0.06 0.24 83 - -0.57 -1.91 171 -2.14 30 0.05
Issuance of Common Equity		 - 0.24 0.00 - - - 53 -3.56 30 -0.09
Other Financing Activities, net		 0.01 0.00 0.20 - - - 118 1.43 0.04 0.14

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets		 322 70 215
Total Current Assets		 275 67 212
Cash & Equivalents		 48 35 20
Restricted Cash		 0.00 0.00 0.11
Short-Term Investments		 220 31 189
Prepaid Expenses		 7.14 1.45 2.77
Plant, Property, & Equipment, net		 23 0.05 0.65
Total Noncurrent Assets		 24 3.08 2.74
Other Noncurrent Operating Assets		 8.59 3.08 2.74
Total Liabilities & Shareholders' Equity		 322 70 215
Total Liabilities		 26 20 11
Total Current Liabilities		 13 19 10
Accounts Payable		 2.61 5.71 4.26
Accrued Expenses		 2.59 13 6.15
Total Noncurrent Liabilities		 13 1.18 0.81
Other Noncurrent Operating Liabilities		 13 1.18 0.81
Commitments & Contingencies		 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 0.00 143 0.00
Total Equity & Noncontrolling Interests		 296 -93 204
Total Preferred & Common Equity		 296 -93 204
Total Common Equity		 296 -93 204
Common Stock		 540 2.53 349
Retained Earnings		 -242 -95 -145
Accumulated Other Comprehensive Income / (Loss)		 -1.05 0.01 0.20

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 335 310 287 266 217 203 224
Total Current Assets		 298 270 251 239 217 199 221
Cash & Equivalents		 56 70 129 183 200 84 41
Restricted Cash		 - - - - 0.11 0.11 0.11
Short-Term Investments		 235 194 118 51 13 112 176
Prepaid Expenses		 6.81 6.21 2.88 4.78 3.28 3.12 3.48
Plant, Property, & Equipment, net		 13 33 18 13 0.05 0.16 0.37
Total Noncurrent Assets		 23 6.62 18 15 0.60 3.13 2.93
Other Noncurrent Operating Assets		 9.68 6.62 18 15 0.60 3.13 2.93
Total Liabilities & Shareholders' Equity		 335 310 287 266 217 203 224
Total Liabilities		 18 34 63 62 19 9.72 8.73
Total Current Liabilities		 14 14 12 13 19 8.58 7.71
Accounts Payable		 3.97 1.99 2.72 3.75 7.13 4.41 2.76
Accrued Expenses		 1.65 7.91 4.37 3.45 12 4.18 4.95
Total Noncurrent Liabilities		 4.87 19 51 50 0.27 1.14 1.02
Other Noncurrent Operating Liabilities		 4.87 19 51 50 0.27 1.14 1.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 316 276 224 204 198 193 215
Total Preferred & Common Equity		 316 276 224 204 198 193 215
Total Common Equity		 316 276 224 204 198 193 215
Common Stock		 536 543 546 548 310 315 347
Retained Earnings		 -218 -266 -322 -344 -112 -122 -132
Accumulated Other Comprehensive Income / (Loss)		 -1.60 -0.47 -0.27 -0.10 -0.00 -0.06 0.52

Annual Metrics and Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -43.23% 26.84% 15.12%
EBIT Growth		 -42.81% 28.42% 19.37%
NOPAT Growth		 -74.77% 31.44% 19.08%
Net Income Growth		 -42.81% 30.76% 28.87%
EPS Growth		 24.90% -1,840.76% 93.45%
Operating Cash Flow Growth		 -66.46% 31.37% 1.64%
Free Cash Flow Firm Growth		 -0.77% 71.31% -123.61%
Invested Capital Growth		 80.10% -218.65% 66.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -6.72% -0.43% 47.32%
EBIT Q/Q Growth		 -5.81% -0.34% 51.46%
NOPAT Q/Q Growth		 -7.98% 2.38% 55.31%
Net Income Q/Q Growth		 -33.54% 1.28% 56.51%
EPS Q/Q Growth		 -132.74% -48.30% -113.64%
Operating Cash Flow Q/Q Growth		 -8.42% 2.36% 41.14%
Free Cash Flow Firm Q/Q Growth		 0.00% -115.89% 57.37%
Invested Capital Q/Q Growth		 12.10% 49.59% -160.69%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.74% 100.00%
Interest Burden Percent		 100.00% 96.97% 85.33%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.71% -40.33% -39.07%
Cash Return on Invested Capital (CROIC)		 -803.61% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.71% -23.66% -17.08%
Return on Equity Simple (ROE_SIMPLE)		 -34.11% 75.47% -24.39%
Net Operating Profit after Tax (NOPAT)		 -74 -51 -41
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.21% -11.03% -6.36%
Return On Investment Capital (ROIC_SIMPLE)		 - 54.69% -20.10%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -101 -72 -58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -100 -73 -62
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.65 0.00 3.89
Price to Tangible Book Value (P/TBV)		 0.65 0.00 3.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.97 -1.01 -1.08
Leverage Ratio		 1.06 1.13 1.12
Compound Leverage Factor		 1.06 1.10 0.96
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 282.94% 0.00%
Common Equity to Total Capital		 100.00% -182.94% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 3.41 0.17 41.74
Noncontrolling Interest Sharing Ratio		 0.00% 41.33% 56.28%
Liquidity Ratios		 - - -
Current Ratio		 21.11 3.63 20.36
Quick Ratio		 20.57 3.55 20.09
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -80 -23 -51
Operating Cash Flow to CapEx		 -1,334.24% -201,266.67% -12,690.38%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 13 -15 -5.06
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.67 -28 10
Enterprise Value (EV)		 -90 230 585
Market Capitalization		 193 152 794
Book Value per Share		 $5.10 ($1.60) $7.42
Tangible Book Value per Share		 $5.10 ($1.60) $7.42
Total Capital		 296 51 204
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -284 -66 -209
Capital Expenditures (CapEx)		 6.59 0.03 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.91 -17 -7.63
Debt-free Net Working Capital (DFNWC)		 262 49 202
Net Working Capital (NWC)		 262 49 202
Net Nonoperating Expense (NNE)		 27 19 8.74
Net Nonoperating Obligations (NNO)		 -284 -66 -209
Total Depreciation and Amortization (D&A)		 0.75 -1.04 -3.96
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Basic Shares Outstanding		 54.87M 57.02M 21.28M
Adjusted Diluted Earnings per Share		 ($1.84) ($2.19) ($2.34)
Adjusted Weighted Average Diluted Shares Outstanding		 54.87M 57.02M 21.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.16M 58.24M 27.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -74 -51 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.08% -3.54% 0.00%

Quarterly Metrics and Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -70.85% -33.95% 50.27% 40.79% 16.68% -1.26% -39.78% 8.90% 30.21% 34.14%
EBIT Growth		 -69.15% -29.30% 51.19% 42.25% 19.11% -1.01% -37.62% 15.09% 35.13% 38.45%
NOPAT Growth		 -79.11% -41.24% 51.40% 44.13% 24.05% 6.59% -27.52% 4.06% 34.84% 39.07%
Net Income Growth		 -69.15% -3,257.77% 50.96% 43.22% 23.51% 3.69% -31.40% 30.37% 45.90% 46.60%
EPS Growth		 -60.71% -106.12% -1,254.17% -1,468.75% -2,037.78% -2,704.65% 45.69% 94.69% 96.05% 116.34%
Operating Cash Flow Growth		 -44.13% -43.84% 39.75% 38.79% 41.09% 6.51% -87.04% -16.79% 19.16% 56.71%
Free Cash Flow Firm Growth		 -59.05% 0.00% 56.98% 174.89% 212.05% 142.49% 236.73% -229.50% -235.20% -299.87%
Invested Capital Growth		 119.44% 80.10% 31.97% -337.29% -363.85% -218.65% -225.54% 86.31% 93.53% 66.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 2.88% -1.31% 49.16% -18.35% -36.67% -23.14% 74.49% 22.86% -4.70% -16.20%
EBIT Q/Q Growth		 4.84% 0.83% 48.24% -18.21% -33.31% -23.83% 76.60% 27.06% -1.84% -17.50%
NOPAT Q/Q Growth		 2.32% -2.28% 52.84% -18.57% -32.80% -25.79% 80.52% 10.79% 9.80% -17.61%
Net Income Q/Q Growth		 4.84% 0.34% 48.49% -16.23% -28.21% -25.49% 77.47% 38.41% 0.38% -23.86%
EPS Q/Q Growth		 6.25% 4.44% -1,411.63% -15.85% -27.76% -25.36% -128.86% 88.67% 5.00% 618.42%
Operating Cash Flow Q/Q Growth		 -0.56% -0.95% 42.94% -5.67% 3.22% -60.22% 47.82% 34.01% 33.01% 14.20%
Free Cash Flow Firm Q/Q Growth		 23.09% 0.42% 51.75% 302.66% 15.07% -62.24% 153.72% -291.94% -20.13% 44.18%
Invested Capital Q/Q Growth		 11.68% 12.10% -4.80% -299.10% -24.19% 49.59% -0.73% 78.29% 41.27% -160.69%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.50% 100.00% 100.00% 100.00% 99.25% 100.00% 100.00% 100.00% 100.01%
Interest Burden Percent		 100.00% 100.00% 100.00% 98.32% 94.56% 96.55% 95.48% 80.63% 78.87% 83.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -21.12% -29.71% -27.57% -27.26% -27.23% -40.33% -53.79% -59.04% -54.59% -39.07%
Cash Return on Invested Capital (CROIC)		 0.00% -803.61% -633.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -21.12% -29.71% -27.57% -27.26% -27.23% -23.66% -53.79% -59.04% -54.59% -17.08%
Return on Equity Simple (ROE_SIMPLE)		 -23.91% 0.00% -31.82% -34.21% -34.74% 0.00% -64.38% -63.81% -53.16% 0.00%
Net Operating Profit after Tax (NOPAT)		 -18 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.82% -1.78% -1.25% -1.48% -1.85% -3.55% -2.26% -0.09% -0.51% -1.45%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - 18.87% - - - -5.22%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -24 -13 -15 -20 -25 -17 -13 -13 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -25 -25 -13 -15 -20 -25 -18 -14 -14 -17
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.58 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89
Price to Tangible Book Value (P/TBV)		 0.58 0.65 0.52 0.67 0.70 0.00 6.54 2.29 3.03 3.89
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.97 -0.97 -1.02 -1.04 -1.01 -1.01 -1.07 -1.08 -1.08
Leverage Ratio		 1.05 1.06 1.08 1.14 1.15 1.13 1.11 1.17 1.17 1.12
Compound Leverage Factor		 1.05 1.06 1.08 1.12 1.09 1.09 1.06 0.95 0.92 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 282.94% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -182.94% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.89 4.20 2.18 0.70 0.35 2.41 40.67 27.34 45.00 42.40
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 41.33% 0.00% 0.00% 0.00% 56.28%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 22.07 21.11 18.85 20.47 19.05 3.63 11.47 23.23 28.63 20.36
Quick Ratio		 21.57 20.57 18.42 20.10 18.66 3.55 11.29 22.85 28.16 20.09
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -24 -12 24 27 10 16 -31 -37 -21
Operating Cash Flow to CapEx		 -2,428.09% -2,196.77% -213,300.00% -56,350.00% 0.00% 0.00% 0.00% -11,875.94% -5,688.71% -6,092.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 11 13 12 -24 -30 -15 -15 -3.31 -1.94 -5.06
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 6.19 5.67 2.94 -34 -41 -28 -27 21 28 10
Enterprise Value (EV)		 -121 -90 -122 -96 -90 230 1,082 245 436 585
Market Capitalization		 185 193 143 151 144 152 1,295 441 653 794
Book Value per Share		 $5.44 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42
Tangible Book Value per Share		 $5.44 $5.10 $4.75 $3.86 $3.52 ($1.60) $42.01 $7.56 $7.83 $7.42
Total Capital		 316 296 276 224 204 51 198 193 215 204
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -305 -284 -264 -247 -234 -66 -213 -196 -217 -209
Capital Expenditures (CapEx)		 0.92 1.02 0.01 0.02 0.00 0.00 0.00 0.13 0.19 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.72 -5.91 -8.13 -7.76 -7.74 -17 -16 -5.46 -4.23 -7.63
Debt-free Net Working Capital (DFNWC)		 285 262 256 239 226 49 198 191 213 202
Net Working Capital (NWC)		 285 262 256 239 226 49 198 191 213 202
Net Nonoperating Expense (NNE)		 6.37 5.87 3.84 4.25 4.97 6.20 5.39 0.21 1.15 1.99
Net Nonoperating Obligations (NNO)		 -305 -284 -264 -248 -234 -66 -213 -196 -217 -209
Total Depreciation and Amortization (D&A)		 0.09 -0.44 0.00 -0.02 -0.52 -0.51 -0.27 -0.94 -1.35 -1.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97
Adjusted Weighted Average Basic Shares Outstanding		 55.21M 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.43) ($0.43) ($0.97) ($0.39) ($12.06) ($3.53) ($0.40) ($0.38) $1.97
Adjusted Weighted Average Diluted Shares Outstanding		 55.21M 54.87M 55.86M 56.75M 57.26M 1.96M 4.72M 25.61M 27.17M 21.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.15M 58.16M 58.10M 57.98M 58.00M 58.24M 25.53M 27.50M 27.50M 27.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -19 -8.83 -10 -14 -17 -11 -10 -9.06 -11
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.08% 0.00% 0.00% 0.00% -3.54% 0.00% 0.00% 0.44% 0.00%

Frequently Asked Questions About LENZ Therapeutics' Financials

When does LENZ Therapeutics's financial year end?

According to the most recent income statement we have on file, LENZ Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has LENZ Therapeutics' net income changed over the last 2 years?

LENZ Therapeutics' net income appears to be on a downward trend, with a most recent value of -$49.77 million in 2024, falling from -$101.05 million in 2022. The previous period was -$69.97 million in 2023.

What is LENZ Therapeutics's operating income?
LENZ Therapeutics's total operating income in 2024 was -$58.61 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $58.61 million
How has LENZ Therapeutics revenue changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does LENZ Therapeutics have?

LENZ Therapeutics' total liabilities were at $11.22 million at the end of 2024, a 43.0% decrease from 2023, and a 56.2% decrease since 2022.

How much cash does LENZ Therapeutics have?

In the past 2 years, LENZ Therapeutics' cash and equivalents has ranged from $20.16 million in 2024 to $47.73 million in 2022, and is currently $20.16 million as of their latest financial filing in 2024.

How has LENZ Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, LENZ Therapeutics' book value per share changed from 5.10 in 2022 to 7.42 in 2024, a change of 45.6%.


Related Companies

This page (NASDAQ:LENZ) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...
Priority Gold | Sponsored
Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
Crypto 101 Media | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored